Health Ministry partners with Takeda for US$30m plasma ecosystem

Jakarta (ANTARA) - The Indonesian Health Ministry partnered with global biopharmaceutical giant Takeda to establish the country’s first plasma-derived medicinal product (PDMP) ecosystem, supported by an initial US$30 million investment.

The initiative aims to significantly strengthen national health resilience and expand public access to essential plasma-based therapies across the archipelago.

Health Minister Budi Gunadi Sadikin stated that the landmark agreement reflects the government's firm commitment to localizing advanced healthcare manufacturing and shielding the country from global supply chain vulnerabilities.

"Through this partnership with Takeda, we hope to strengthen the national healthcare system while preparing Indonesia to face future health challenges," Budi said in his statement on Monday.

Under the agreement, Takeda has been officially designated as a pharmaceutical company authorized to conduct plasma fractionation.

This mandate allows the company to gradually collect and fractionate plasma as part of the foundational development of the national plasma industry ecosystem.

The initiative is heavily backed by the economic sector, drawing active involvement from the Investment and Downstreaming Ministry and the Coordinating Ministry for Economic Affairs.

The multi-year project stands as the first initiative in Southeast Asia dedicated to building a sustainable, high-quality plasma collection system alongside large-scale pharmaceutical manufacturing.

In the initial phase, Takeda will inject up to US$30 million over a two-year period to establish a pilot network of plasma banks in Indonesia.

The outcomes of this initial phase will serve as the baseline for a joint evaluation with the Health Ministry to assess the operational model's feasibility before expanding it into a comprehensive national network.

All facilities will implement strict international quality standards and regulatory frameworks, leveraging Takeda’s extensive global expertise in plasma donor management.

Beyond patient care, officials note the project will serve as a major economic catalyst.

"This investment is strategic," Investment and Downstreaming Minister Rosan P. Roeslani noted.

"In addition to bringing new investment, this partnership opens up opportunities for technology transfer, national human resource development and job creation. It supports our vision of making Indonesia a regional hub for healthcare innovation and advanced drug manufacturing,” he explained.

The development of the network is also anticipated to generate highly skilled jobs for healthcare workers and laboratory technicians, while simultaneously boosting local human resource capacity through knowledge and technology transfer.

In addition to the plasma bank network, Takeda is exploring the feasibility of constructing a high-tech plasma-derived drug manufacturing facility in Indonesia to cater to both domestic demand and the international market—potentially positioning the country as a key player in the global pharmaceutical supply chain.

The first plasma bank under this partnership is scheduled to begin operations in 2027 as part of Takeda’s global BioLife network.

While the plans for a domestic fractionation facility remain under review, the collected plasma will initially be processed through Takeda’s international manufacturing network—with strict priority given to fulfilling Indonesia’s domestic pharmaceutical needs in compliance with prevailing laws.

Related news: Indonesia pushes access to innovative biopharmaceutical products

Related news: Ministry encourages use of marine biota in biopharmaceutical industry

Translator: Ida Nurcahyani, Yashinta Difa

Editor: Rahmad Nasution

Copyright © ANTARA 2026